Wockhardt Ltd News
Pharma shares slide up to 10% as Trump to announce pharma tariffs 'soon'
Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%
 "Pharma shares slide up to 10% as Trump to announce pharma tariffs 'soon'")
NGL, Zaggle, others from BSE Smallcap freeze in lower circuits of up to 20%
Indo Tech Transformers, V2 Retail, Coffee Day Enterprises, Veritas (India) and Rajoo Engineers are others from the BSE Smallcap index locked in their respective lower circuit on the BSE
 "NGL, Zaggle, others from BSE Smallcap freeze in lower circuits of up to 20%")
Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III
Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with European Medicines Agency (EMA)
 "Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III")
Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria
Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients
 "Wockhardt gains 4% as drug shows 97% efficacy for drug-resistant bacteria")
Wockhardt rises 5% on getting CDSCO's approval for pneumonia curing drug
The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults
 "Wockhardt rises 5% on getting CDSCO's approval for pneumonia curing drug")
Why this pharma stock hit nearly 9-year high; froze at 10% upper circuit?
Wockhardt stock gained 10% to touch Rs 1,536.40; it has outperformed the market by zooming 262% thus far in calendar year 2024, as compared to the 13% rise in the BSE Sensex
 "Why this pharma stock hit nearly 9-year high; froze at 10% upper circuit?")
Wockhardt Q2 results: Net loss narrows to Rs 16 cr, revenue at Rs 809 cr
Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024. The company has reported a net loss of Rs 73 crore in July-September quarter of last fiscal. Revenue from operations stood at Rs 809 crore for the second quarter as compared with Rs 753 crore in the year-ago period, the Mumbai-based drug maker said in a regulatory filing. Shares of the company were trading 0.63 per cent up at Rs 1,189 apiece on BSE.
 "Wockhardt Q2 results: Net loss narrows to Rs 16 cr, revenue at Rs 809 cr")
This pharma stock has zoomed over 380% in Samvat 2080; trades at 8-yr high
Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.
 "This pharma stock has zoomed over 380% in Samvat 2080; trades at 8-yr high")
